Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Exposure to high fat diets and bisphenol (Study ST000670)

C18 NEGATIVE ION MODE (Analysis AN001026)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12
PA 34:0; [M-H]-@7.13	ME183634	1.54	1.06	2.03	0.86	0.53	1.32	0.99	1.03	0.70	1.05	0.88	0.46
PC 35:0; [M-Ac-H]-@7.45	ME183646	0.99	1.02	0.86	0.97	1.33	0.91	1.24	1.16	1.11	0.68	1.09	0.72
PG 36:0; [M-H]-@6.97	ME183719	0.91	0.93	0.71	1.02	1.17	0.91	1.76	0.87	1.48	1.01	0.88	0.52
FFA(24:0)	ME183629	1.07	1.01	1.48	1.09	0.92	1.07	1.27	0.95	0.78	0.66	1.09	1.04
PC 39:6; [M-Ac-H]-@6.41	ME183675	1.08	0.66	1.01	0.92	1.16	0.72	1.71	1.18	0.85	1.03	1.07	1.01
PC 36:0; [M-Ac-H]-@7.74	ME183651	1.00	0.94	1.09	0.93	0.76	0.71	1.35	1.07	1.12	1.10	1.00	1.14
PG 38:4; [M-H]-@6.15	ME183722	0.90	1.17	1.16	0.84	0.88	0.89	1.71	1.04	0.91	1.07	0.88	0.92
PC 28:0; [M-Ac-H]-@5.24	ME183635	0.76	0.73	0.76	1.24	0.78	1.41	1.47	0.83	1.26	1.44	0.49	0.68
PI 36:1; [M-H]-@6.40	ME183724	0.93	1.05	0.82	1.26	0.87	1.28	1.29	0.77	0.62	1.43	0.62	0.92
PC 33:2; [M-Ac-H]-@5.97	ME183641	0.75	1.02	0.53	1.34	1.10	1.32	0.98	1.22	0.97	0.82	0.77	0.83
PI 36:3; [M-H]-@5.49	ME183726	0.77	1.14	0.52	1.45	1.22	1.01	0.79	1.19	0.71	0.88	0.78	1.09
PA 33:2; [M-H]-@1.97	ME183633	1.10	0.96	0.89	1.13	0.91	1.70	0.80	0.71	0.74	0.96	1.09	0.91
FFA(24:3)	ME183632	0.60	1.15	1.09	1.32	0.75	1.38	0.80	0.86	0.95	1.05	1.26	0.86
PE 36:0; [M-H]-@7.86	ME183693	0.98	0.98	0.86	1.00	0.90	1.24	1.16	0.92	1.20	1.02	0.64	0.93
PC 35:1; [M-Ac-H]-@7.01	ME183647	0.95	1.07	0.60	1.06	0.90	1.17	1.12	1.21	0.65	1.04	0.94	1.11
FFA(20:0)	ME183622	0.86	1.03	0.96	1.07	0.91	1.16	0.86	1.01	0.90	1.12	0.93	1.06
FFA(22:0)	ME183625	0.84	1.10	0.94	1.01	0.92	1.15	0.83	0.98	0.92	1.18	0.96	1.03
FFA(16:0)	ME183618	1.00	0.98	0.93	1.04	0.90	1.16	0.92	1.05	0.88	1.03	1.12	0.97
FFA(18:0)	ME183619	0.97	0.99	1.00	1.02	0.94	1.08	0.96	1.03	0.90	1.05	1.06	1.02
FFA(18:1)	ME183620	1.01	0.92	0.79	1.07	0.89	1.27	1.02	1.02	0.88	0.97	1.45	0.83
FFA(18:2)	ME183621	1.05	0.97	0.92	1.13	0.91	1.34	0.90	1.02	0.78	0.91	1.28	0.85
CL 78:3; [M-2H](2-)@7.47	ME183613	0.37	1.10	0.55	1.81	0.86	1.54	0.69	1.44	0.61	1.00	0.28	1.01
PE 40:7; [M-H]-@5.03	ME183715	0.67	0.52	0.58	1.38	0.69	0.75	0.89	1.22	0.80	1.35	1.33	1.73
PC 42:5; [M-Ac-H]-@7.56	ME183687	0.33	1.51	0.27	1.98	0.31	1.19	0.24	1.03	0.35	1.93	0.38	1.43
CL 70:5; [M-2H](2-)@5.92	ME183608	0.42	1.87	0.29	1.76	0.69	1.09	0.39	1.38	0.50	0.84	0.40	1.40
PC 40:2; [M-Ac-H]-@7.96	ME183676	0.35	1.68	0.26	1.64	0.41	1.05	0.29	1.24	0.40	1.55	0.34	1.76
PE 34:2; [M-H]-@6.46	ME183692	0.36	1.53	0.47	1.80	0.34	1.32	0.35	1.32	0.40	1.31	0.33	1.55
CL 70:3; [M-2H](2-)@6.36	ME183607	0.50	1.86	0.39	1.45	0.35	0.99	0.50	1.35	0.43	1.47	0.28	1.52
CL 70:1; [M-2H](2-)@6.86	ME183606	0.57	1.74	0.41	1.47	0.50	1.19	0.48	1.36	0.47	1.21	0.40	1.34
PC 39:4; [M-Ac-H]-@7.14	ME183673	0.57	1.75	0.33	1.66	0.45	1.00	0.47	1.16	0.64	1.31	0.44	1.35
PE 38:2; [M-H]-@7.52	ME183703	0.33	1.80	0.42	1.97	0.46	1.08	0.28	1.17	0.51	1.39	0.36	1.28
PE 40:5; [M-H]-@7.14	ME183711	0.48	1.98	0.42	1.67	0.45	1.07	0.31	0.92	0.58	1.50	0.35	1.30
PC 42:2; [M-Ac-H]-@8.50	ME183685	0.71	1.19	0.41	1.68	0.43	1.02	0.52	1.08	0.55	1.51	0.36	1.67
PI 36:2; [M-H]-@6.01	ME183725	0.62	1.44	0.79	1.28	0.52	1.02	0.51	1.30	0.62	1.04	0.54	1.76
PC 37:2; [M-Ac-H]-@7.17	ME183660	0.63	1.51	0.48	1.48	0.43	1.19	0.54	1.26	0.60	1.12	0.59	1.46
PE 34:1; [M-H]-@6.88	ME183691	0.58	1.40	0.46	1.36	0.55	1.36	0.46	1.40	0.53	1.04	0.54	1.55
PE 36:1; [M-H]-@6.78	ME183695	0.48	1.51	0.50	1.31	0.48	1.24	0.58	1.42	0.56	1.15	0.36	1.64
PI 36:4; [M-H]-@5.29	ME183727	0.59	1.54	0.58	1.09	0.38	1.00	0.48	1.85	0.46	1.16	0.51	1.65
CL 74:5; [M-2H](2-)@6.58	ME183611	0.53	1.46	0.40	1.08	0.35	1.03	0.76	1.62	0.52	1.45	0.45	1.66
PE 36:3; [M-H]-@6.56	ME183698	0.55	1.46	0.38	1.02	0.34	0.97	0.58	1.78	0.53	1.42	0.42	1.73
PC 32:1; [M-Ac-H]-@6.11	ME183638	0.58	1.38	0.46	1.32	0.41	0.99	0.49	1.55	0.71	1.20	0.61	1.58
plasmenyl-PE 38:6; [M-H]-@6.61	ME183755	0.70	1.11	0.53	1.27	0.43	0.89	0.57	1.47	0.69	1.25	0.71	1.78
plasmenyl-PE 36:3; [M-H]-@6.91	ME183747	0.60	1.04	0.48	1.24	0.42	1.05	0.61	1.33	0.64	1.39	0.76	1.88
plasmenyl-PE 36:4; [M-H]-@6.71	ME183748	0.70	1.14	0.48	1.13	0.44	1.15	0.59	1.35	0.73	1.24	0.74	1.72
plasmenyl-PE 38:5; [M-H]-@6.96	ME183754	0.63	1.24	0.43	1.27	0.43	1.06	0.60	1.35	0.63	1.30	0.67	1.74
PC 37:5; [M-Ac-H]-@6.06	ME183663	0.88	1.24	0.39	0.87	0.55	0.84	0.89	1.39	0.61	1.38	0.51	1.83
PE 38:5; [M-H]-@5.11	ME183707	0.57	1.49	0.56	0.97	0.51	0.85	0.75	1.30	0.63	1.49	0.52	1.77
PG 34:2; [M-H]-@5.52	ME183718	0.73	1.16	0.46	1.06	0.41	1.01	0.82	1.45	0.53	1.32	0.56	1.91
CL 74:3; [M-2H](2-)@6.96	ME183610	0.56	1.31	0.66	1.25	0.43	0.90	0.89	1.46	0.50	1.35	0.48	1.72
PE 36:2; [M-H]-@7.02	ME183696	0.57	1.33	0.57	1.15	0.45	1.04	0.77	1.40	0.54	1.32	0.50	1.77
PC 42:4; [M-Ac-H]-@7.98	ME183686	0.56	1.25	0.55	1.18	0.32	0.73	0.66	1.27	0.48	1.74	0.57	2.08
PC 41:5; [M-Ac-H]-@7.42	ME183683	0.47	1.55	0.33	1.19	0.48	1.12	0.46	1.30	0.50	1.61	0.45	1.67
PC 36:6; [M-Ac-H]-@5.46	ME183658	0.67	1.45	0.39	1.18	0.41	0.74	0.50	1.17	0.66	1.80	0.61	1.68
PC 40:4; [M-Ac-H]-@7.43	ME183678	0.48	1.43	0.44	1.30	0.42	0.89	0.55	1.27	0.50	1.84	0.67	1.55
CL 78:9; [M-2H](2-)@6.73	ME183614	0.52	1.62	0.48	1.12	0.41	0.86	0.63	1.32	0.52	1.68	0.60	1.60
PE 38:5; [M-H]-@6.58	ME183706	0.52	1.54	0.37	1.21	0.37	0.90	0.56	1.37	0.52	1.60	0.60	1.69
PC 38:1; [M-Ac-H]-@7.83	ME183665	0.40	1.57	0.42	1.52	0.35	0.97	0.57	1.18	0.64	1.50	0.53	1.61
PC 40:3; [M-Ac-H]-@7.61	ME183677	0.42	1.41	0.37	1.42	0.33	0.99	0.31	1.40	0.47	1.58	0.47	1.90
plasmenyl-PE 34:2; [M-H]-@6.78	ME183744	0.52	1.16	0.39	1.37	0.34	0.99	0.57	1.51	0.48	1.48	0.57	1.89
PC 32:2; [M-Ac-H]-@5.62	ME183639	0.68	1.36	0.46	1.48	0.33	0.89	0.52	1.34	0.51	1.38	0.64	1.71
PC 38:2; [M-Ac-H]-@7.44	ME183667	0.53	1.33	0.48	1.42	0.38	1.00	0.59	1.37	0.53	1.51	0.52	1.63
plasmenyl-PE 38:2; [M-H]-@7.91	ME183751	0.59	1.81	0.77	1.26	0.55	0.92	0.68	0.78	0.64	1.78	0.72	1.08
PE 36:5; [M-H]-@5.93	ME183701	0.43	2.01	0.48	0.84	0.37	0.98	0.34	1.39	0.47	1.66	0.49	1.70
CL 78:11; [M-2H](2-)@6.10	ME183612	0.71	2.07	0.46	1.13	0.42	0.75	0.67	1.04	0.66	1.59	0.53	1.30
CL 82:13; [M-2H](2-)@6.42	ME183616	0.52	1.91	0.59	1.05	0.48	0.90	0.65	0.95	0.68	1.72	0.45	1.43
PE 40:7; [M-H]-@6.40	ME183714	0.46	1.97	0.56	1.18	0.43	0.83	0.56	1.01	0.68	1.68	0.56	1.42
PE 40:6; [M-H]-@5.46	ME183712	0.60	1.77	0.54	1.13	0.45	0.70	0.44	1.24	0.85	1.50	0.40	1.57
PC 37:1; [M-Ac-H]-@7.55	ME183659	0.51	1.66	0.47	1.19	0.43	1.03	0.74	1.09	0.87	1.36	0.42	1.54
PC 42:9; [M-Ac-H]-@6.14	ME183689	0.46	1.81	0.41	1.14	0.41	0.88	0.82	1.14	0.60	1.53	0.52	1.66
PE 36:4; [M-H]-@6.25	ME183699	0.58	1.67	0.37	1.08	0.34	1.04	0.54	1.45	0.61	1.59	0.51	1.44
PI 38:5; [M-H]-@5.48	ME183730	0.68	1.78	0.42	1.15	0.42	0.95	0.59	1.27	0.61	1.46	0.46	1.46
CL 82:11; [M-2H](2-)@6.82	ME183615	0.59	1.72	0.45	1.12	0.48	0.84	0.60	1.13	0.76	1.54	0.57	1.51
PE 38:6; [M-H]-@6.20	ME183708	0.75	1.65	0.59	1.10	0.44	0.79	0.64	1.16	0.66	1.48	0.70	1.50
PC 42:7; [M-Ac-H]-@6.82	ME183688	0.66	1.63	0.39	1.34	0.45	0.73	0.57	1.20	0.62	1.53	0.80	1.46
PE 37:4; [M-H]-@6.72	ME183702	0.56	1.73	0.33	1.22	0.54	0.89	0.68	1.12	0.66	1.45	0.75	1.44
PC 30:0; [M-Ac-H]-@5.96	ME183636	0.70	1.08	0.97	1.07	0.57	1.22	0.49	1.53	0.72	1.08	0.62	1.49
PI 34:2; [M-H]-@5.34	ME183723	0.69	1.26	0.97	1.16	0.92	1.02	0.78	1.46	0.62	1.03	0.79	1.06
PE 40:4; [M-H]-@7.43	ME183709	0.43	1.40	0.25	1.22	0.72	1.26	0.48	1.02	0.63	1.33	0.94	1.65
PE 40:5; [M-H]-@6.42	ME183710	0.55	1.66	0.47	1.04	0.60	1.33	0.71	1.06	0.76	1.23	0.65	1.36
CL 82:15; [M-2H](2-)@6.09	ME183617	0.53	1.58	0.47	1.11	0.90	1.19	0.55	1.03	0.56	1.36	0.51	1.47
PE 40:8; [M-H]-@6.03	ME183716	0.58	1.27	0.56	1.01	0.96	1.22	0.54	0.96	0.66	1.31	0.57	1.70
FFA(20:1)	ME183623	0.78	1.07	0.62	1.35	0.68	1.39	0.67	1.14	0.62	1.34	0.94	1.00
FFA(20:2)	ME183624	0.90	1.00	0.70	1.26	0.76	1.23	0.82	1.12	0.72	1.24	1.16	0.93
FFA(22:1)	ME183626	0.77	1.28	0.67	1.35	0.57	1.32	0.53	1.17	0.58	1.28	0.68	1.23
FFA(22:2)	ME183627	0.65	1.25	0.57	1.55	0.60	1.37	0.41	1.21	0.48	1.36	0.76	1.16
FFA(22:3)	ME183628	0.69	1.24	0.63	1.38	0.76	1.19	0.78	1.06	0.64	1.33	0.76	1.13
CL 74:1; [M-2H](2-)@7.20	ME183609	0.58	1.22	0.53	1.41	0.70	1.36	0.77	1.20	0.63	1.27	0.60	1.17
PE 36:1; [M-H]-@7.44	ME183694	0.65	1.34	0.54	1.39	0.72	1.40	0.71	1.10	0.66	1.14	0.55	1.20
PC 35:2; [M-Ac-H]-@6.57	ME183648	0.79	1.34	0.76	1.35	0.66	1.10	0.79	0.95	0.81	1.19	0.62	1.22
PC 35:4; [M-Ac-H]-@5.94	ME183650	0.91	1.40	0.63	1.32	0.68	0.85	0.86	1.05	0.77	1.11	0.65	1.34
plasmenyl-PE 40:5; [M-H]-@7.40	ME183757	0.63	1.47	0.57	1.48	0.65	0.87	0.67	0.93	0.81	1.37	0.65	1.33
PC 35:3; [M-Ac-H]-@6.11	ME183649	0.67	1.41	0.51	1.28	0.57	1.03	0.69	1.12	0.87	1.40	0.56	1.26
plasmenyl-PE 38:4; [M-H]-@7.25	ME183753	0.60	1.45	0.55	1.28	0.63	1.11	0.56	1.11	0.77	1.36	0.67	1.29
PC 42:10; [M-Ac-H]-@5.74	ME183684	0.70	1.37	0.77	1.26	0.67	0.80	0.72	0.99	0.63	1.45	0.79	1.49
plasmenyl-PE 42:4; [M-H]-@8.18	ME183759	0.77	1.48	0.61	1.35	0.60	0.79	0.56	1.15	0.68	1.48	0.76	1.25
PC 37:6; [M-Ac-H]-@5.82	ME183664	0.87	1.31	0.51	0.96	0.56	1.14	0.60	1.08	0.91	1.38	0.94	1.28
plasmenyl-PE 34:1; [M-H]-@7.18	ME183743	0.85	1.17	0.63	1.15	0.62	1.01	0.57	1.18	0.57	1.56	1.07	1.25
plasmenyl-PE 36:5; [M-H]-@6.37	ME183749	0.66	1.08	0.61	1.31	0.50	1.14	0.53	1.14	0.79	1.58	0.64	1.41
plasmenyl-PE 40:6; [M-H]-@7.08	ME183758	0.84	1.06	0.66	1.01	0.63	0.85	0.84	1.18	0.86	1.26	0.92	1.60
plasmenyl-PE 38:3; [M-H]-@7.44	ME183752	0.86	1.06	0.56	1.00	0.59	0.98	0.73	1.26	0.84	1.38	0.79	1.49
plasmenyl-PE 40:4; [M-H]-@7.77	ME183756	0.73	1.15	0.55	1.03	0.56	0.91	0.79	1.27	0.75	1.38	0.79	1.65
PC 40:5; [M-Ac-H]-@7.09	ME183679	0.67	1.13	0.68	1.12	0.61	0.75	0.92	1.21	0.83	1.50	0.77	1.51
PC 40:7; [M-Ac-H]-@6.18	ME183681	0.80	1.15	0.72	1.10	0.55	0.76	0.86	1.09	0.81	1.47	0.86	1.53
PC 38:7; [M-Ac-H]-@5.61	ME183672	0.77	1.19	0.63	1.13	0.49	0.80	0.69	1.20	0.71	1.53	0.81	1.61
PC 40:8; [M-Ac-H]-@5.84	ME183682	0.71	1.13	0.57	1.13	0.50	0.90	0.82	1.16	0.68	1.62	0.90	1.54
lysoPE 22:4; [M-H]-@1.90	ME183739	0.55	1.28	0.63	1.40	0.48	1.01	0.70	1.29	0.71	1.29	0.83	1.40
PE 38:3; [M-H]-@7.24	ME183704	0.76	1.48	0.42	1.00	0.42	1.00	0.55	1.30	0.62	1.35	0.81	1.69
PE 38:4; [M-H]-@6.99	ME183705	0.70	1.38	0.47	1.03	0.50	1.01	0.66	1.32	0.69	1.40	0.74	1.53
PE 36:4; [M-H]-@5.00	ME183700	0.70	1.33	0.47	1.01	0.62	0.93	0.43	1.17	0.71	1.40	0.81	1.77
PC 38:2; [M-Ac-H]-@6.88	ME183666	0.72	1.22	0.61	1.14	0.53	1.01	0.61	1.16	0.82	1.31	0.79	1.60
PE 40:6; [M-H]-@6.87	ME183713	0.67	1.37	0.50	1.20	0.48	0.86	0.56	1.24	0.73	1.40	0.76	1.64
lysoPE 22:5; [M-H]-@1.64	ME183740	0.68	1.38	0.36	1.17	0.46	0.91	0.73	1.35	0.63	1.58	0.92	1.32
PC 34:4; [M-Ac-H]-@5.57	ME183645	0.68	1.44	0.39	1.21	0.36	1.05	0.53	1.34	0.59	1.52	0.74	1.49
PC 34:3; [M-Ac-H]-@5.81	ME183644	0.67	1.35	0.45	1.20	0.42	1.05	0.59	1.34	0.68	1.52	0.70	1.39
PC 36:5; [M-Ac-H]-@5.66	ME183657	0.67	1.39	0.41	1.21	0.41	1.00	0.59	1.33	0.66	1.51	0.75	1.44
PC 34:1; [M-Ac-H]-@6.66	ME183642	0.74	1.29	0.55	1.11	0.57	1.12	0.68	1.41	0.68	1.27	0.74	1.31
PC 36:3; [M-Ac-H]-@6.36	ME183655	0.76	1.26	0.57	1.12	0.57	1.08	0.68	1.35	0.68	1.33	0.74	1.35
PC 34:2; [M-Ac-H]-@6.23	ME183643	0.72	1.34	0.54	1.22	0.50	1.06	0.61	1.39	0.64	1.34	0.60	1.43
PC 36:4; [M-Ac-H]-@6.08	ME183656	0.74	1.31	0.57	1.18	0.54	0.92	0.60	1.34	0.74	1.36	0.69	1.43
plasmenyl-PE 36:2; [M-H]-@7.37	ME183746	0.65	1.26	0.53	1.01	0.57	1.02	0.80	1.21	0.70	1.63	0.78	1.39
PC 38:5; [M-Ac-H]-@6.41	ME183670	0.80	1.32	0.56	1.02	0.57	0.92	0.78	1.25	0.77	1.40	0.87	1.34
PC 38:6; [M-Ac-H]-@6.02	ME183671	0.78	1.28	0.48	1.12	0.50	0.96	0.63	1.23	0.84	1.44	0.81	1.39
lysoPE 16:1; [M-H]-@1.19	ME183732	0.89	1.27	0.59	1.00	0.61	0.86	0.97	1.72	0.58	1.08	0.83	1.30
PI 38:3; [M-H]-@6.24	ME183728	0.77	1.05	0.80	0.98	0.59	0.86	0.68	1.43	0.76	1.14	1.01	1.68
PC 32:0; [M-Ac-H]-@6.61	ME183637	0.98	1.16	0.81	1.05	0.78	1.15	0.57	1.26	0.83	1.04	0.90	1.12
PC 33:1; [M-Ac-H]-@6.42	ME183640	0.96	1.15	0.91	1.09	0.52	0.97	0.77	1.42	0.80	1.04	1.13	1.15
lysoPE 16:0; [M-H]-@1.68	ME183731	0.86	1.27	0.59	1.00	0.60	0.90	0.74	1.31	0.85	1.13	1.15	1.34
lysoPE 18:0; [M-H]-@2.47	ME183733	0.88	1.19	0.73	0.91	0.66	0.88	0.84	1.27	0.90	1.17	1.10	1.29
lysoPE 18:1; [M-H]-@1.82	ME183734	0.86	1.23	0.66	1.02	0.60	1.01	0.90	1.39	0.79	1.05	0.98	1.28
lysoPE 18:2; [M-H]-@1.36	ME183735	0.84	1.20	0.62	1.11	0.62	0.95	1.02	1.44	0.68	1.12	0.79	1.33
lysoPE 20:3; [M-H]-@1.64	ME183737	0.61	1.23	0.47	1.20	0.58	1.03	0.81	1.27	0.87	1.22	0.94	1.37
PC 36:2; [M-Ac-H]-@6.78	ME183653	0.78	1.18	0.67	1.12	0.63	0.98	0.85	1.24	0.78	1.26	0.85	1.36
PC 36:2; [M-Ac-H]-@6.86	ME183654	0.78	1.18	0.67	1.12	0.63	0.98	0.85	1.24	0.78	1.26	0.85	1.36
PG 36:3; [M-H]-@5.52	ME183721	0.69	1.17	0.70	1.03	0.66	1.21	0.79	1.51	0.52	1.25	0.86	1.27
plasmenyl-PE 38:1; [M-H]-@8.15	ME183750	0.79	1.10	0.66	1.00	0.55	1.25	0.77	1.19	0.68	1.35	0.88	1.43
PG 36:2; [M-H]-@6.15	ME183720	0.78	1.16	0.72	0.80	0.71	1.07	1.15	1.16	0.88	1.41	0.68	1.25
PC 40:6; [M-Ac-H]-@6.68	ME183680	0.95	1.07	0.69	0.86	0.71	0.75	1.02	1.02	1.09	1.42	1.11	1.24
plasmenyl-PE 42:6; [M-H]-@7.77	ME183761	1.06	1.04	0.72	0.90	0.62	0.84	1.06	0.93	1.07	1.28	1.16	1.28
lysoPE 22:6; [M-H]-@1.30	ME183741	0.93	1.10	0.58	0.93	0.74	0.76	1.03	1.18	0.99	1.42	1.25	1.03
lysoPE 20:4; [M-H]-@1.36	ME183738	0.84	1.20	0.51	1.04	0.69	0.88	0.97	1.28	0.86	1.33	1.07	1.10
PC 36:1; [M-Ac-H]-@7.28	ME183652	0.78	1.16	0.65	0.94	0.70	0.92	1.09	1.21	0.92	1.27	1.09	1.20
PC 44:4; [M-Ac-H]-@8.48	ME183690	0.87	1.16	0.67	0.92	0.76	0.89	1.01	1.24	0.74	1.33	1.19	1.17
PC 38:3; [M-Ac-H]-@7.09	ME183668	0.79	1.43	0.42	1.16	0.53	0.84	0.78	0.99	0.96	1.51	0.52	1.42
PC 37:4; [M-Ac-H]-@6.55	ME183662	0.74	1.51	0.77	1.00	0.58	0.92	0.79	0.81	1.03	1.38	0.77	1.36
PC 38:4; [M-Ac-H]-@6.81	ME183669	0.85	1.34	0.60	1.00	0.72	0.73	0.97	0.90	1.04	1.46	0.81	1.27
PI 38:4; [M-H]-@5.96	ME183729	0.81	1.33	0.67	0.94	0.64	0.78	0.80	1.06	0.94	1.32	0.90	1.51
PC 39:5; [M-Ac-H]-@6.65	ME183674	0.89	1.06	0.74	1.21	0.64	0.84	0.67	0.76	0.84	1.50	1.12	1.49
plasmenyl-PE 42:5; [M-H]-@8.05	ME183760	0.89	1.13	0.89	1.14	0.85	0.72	0.73	0.98	1.01	1.24	0.93	1.27
PE 42:8; [M-H]-@6.56	ME183717	0.31	1.04	0.87	1.73	0.98	0.94	0.73	0.70	0.89	1.70	0.75	1.04
plasmenyl-PE 36:1; [M-H]-@7.73	ME183745	0.50	1.39	0.30	2.07	0.56	1.71	0.33	0.71	0.78	1.18	0.70	0.94
FFA(24:1)	ME183630	0.61	1.37	0.65	1.94	0.74	1.21	0.51	0.98	0.62	0.97	0.85	1.06
FFA(24:2)	ME183631	0.55	1.26	0.83	2.06	0.68	1.12	0.42	0.94	0.71	0.99	1.00	1.07
PE 36:3; [M-H]-@5.16	ME183697	0.60	1.32	0.66	1.54	0.62	1.22	0.17	1.07	0.62	1.09	0.98	1.53
PC 37:3; [M-Ac-H]-@6.66	ME183661	0.57	1.56	0.63	1.62	0.50	0.94	0.50	0.96	0.75	1.20	1.12	1.27
lysoPE 20:2; [M-H]-@1.95	ME183736	0.72	1.52	0.60	1.64	0.57	0.95	0.42	0.86	0.74	1.34	0.80	1.25
plasmenyl-PE 32:0; [M-H]-@7.09	ME183742	0.79	1.26	0.53	1.64	0.66	0.87	0.58	0.90	0.72	1.51	0.90	1.15

Factors:

F1	Diet:Control + BPA Chow \| Sex:F
F2	Diet:Control + BPA Chow \| Sex:M
F3	Diet:Control Chow \| Sex:F
F4	Diet:Control Chow \| Sex:M
F5	Diet:Mediterranean + BPA Chow \| Sex:F
F6	Diet:Mediterranean + BPA Chow \| Sex:M
F7	Diet:Mediterranean HFD Chow \| Sex:F
F8	Diet:Mediterranean HFD Chow \| Sex:M
F9	Diet:Western + BPA Chow \| Sex:F
F10	Diet:Western + BPA Chow \| Sex:M
F11	Diet:Western HFD Chow \| Sex:F
F12	Diet:Western HFD Chow \| Sex:M

Data matrix